Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel Buys 4,500 Shares

Greenwich LifeSciences, Inc. (NASDAQ:GLSIGet Rating) CEO Snehal Patel purchased 4,500 shares of Greenwich LifeSciences stock in a transaction dated Thursday, June 9th. The shares were purchased at an average cost of $10.90 per share, for a total transaction of $49,050.00. Following the transaction, the chief executive officer now owns 1,243,453 shares in the company, valued at approximately $13,553,637.70. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Snehal Patel also recently made the following trade(s):

  • On Tuesday, June 7th, Snehal Patel purchased 6,000 shares of Greenwich LifeSciences stock. The shares were purchased at an average cost of $8.55 per share, for a total transaction of $51,300.00.
  • On Thursday, June 2nd, Snehal Patel bought 6,774 shares of Greenwich LifeSciences stock. The stock was bought at an average price of $7.38 per share, with a total value of $49,992.12.
  • On Thursday, April 21st, Snehal Patel bought 6,000 shares of Greenwich LifeSciences stock. The stock was bought at an average price of $16.09 per share, with a total value of $96,540.00.
  • On Tuesday, April 19th, Snehal Patel bought 6,000 shares of Greenwich LifeSciences stock. The stock was bought at an average price of $16.74 per share, with a total value of $100,440.00.

NASDAQ:GLSI opened at $10.52 on Friday. The company has a fifty day simple moving average of $12.44 and a two-hundred day simple moving average of $19.36. Greenwich LifeSciences, Inc. has a 52 week low of $6.90 and a 52 week high of $48.96.

Several hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. grew its stake in shares of Greenwich LifeSciences by 150.2% during the first quarter. Vanguard Group Inc. now owns 375,200 shares of the company’s stock worth $7,362,000 after purchasing an additional 225,213 shares in the last quarter. BlackRock Inc. grew its stake in shares of Greenwich LifeSciences by 9.2% during the fourth quarter. BlackRock Inc. now owns 237,959 shares of the company’s stock worth $5,790,000 after purchasing an additional 20,105 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Greenwich LifeSciences by 18.4% during the fourth quarter. Geode Capital Management LLC now owns 67,420 shares of the company’s stock worth $1,640,000 after purchasing an additional 10,501 shares in the last quarter. State Street Corp lifted its position in Greenwich LifeSciences by 1.8% in the first quarter. State Street Corp now owns 66,485 shares of the company’s stock valued at $1,304,000 after acquiring an additional 1,176 shares during the last quarter. Finally, Millennium Management LLC lifted its position in Greenwich LifeSciences by 101.4% in the fourth quarter. Millennium Management LLC now owns 30,414 shares of the company’s stock valued at $740,000 after acquiring an additional 15,316 shares during the last quarter. Hedge funds and other institutional investors own 6.15% of the company’s stock.

Separately, Zacks Investment Research downgraded shares of Greenwich LifeSciences from a “buy” rating to a “hold” rating in a research note on Thursday.

About Greenwich LifeSciences (Get Rating)

Greenwich LifeSciences, Inc, a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.

Featured Stories

Insider Buying and Selling by Quarter for Greenwich LifeSciences (NASDAQ:GLSI)

Want More Great Investing Ideas?

Receive News & Ratings for Greenwich LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Greenwich LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.